Pyramid Inventions Spółka z Ograniczoną Odpowiedzialnością w Likwidacji (KRS 0001073380, NIP 6762657894) is a Polish company, headquartered in Kraków, Małopolskie voivodeship. Pyramid Inventions Spółka z Ograniczoną Odpowiedzialnością w Likwidacji operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since December 5, 2023. Pyramid Inventions Spółka z Ograniczoną Odpowiedzialnością w Likwidacji's most recently reported net revenue was 0 PLN for 2026.
Negative equity
Negative equity in 3 of 3 available reporting years.
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Pyramid Inventions
Identity
- Name
- Pyramid Inventions Spółka z Ograniczoną Odpowiedzialnością w Likwidacji
- Legal form
- Limited Liability Company (LLC)
- Founded
- December 5, 2023
- Registry status as of
- December 3, 2025
- Latest entry
- August 8, 2025
- Founding act
- 01.12.2023
Articles of association history (1)
- December 1, 2023: 01.12.2023
Activities
Other activities
Address and contact
- Address
- RYNEK GŁÓWNY, 44, 31-017, KRAKÓW, POLSKA
- Voivodeship
- MAŁOPOLSKIE
- District
- KRAKÓW
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
Risk and payment profile - Pyramid Inventions
Credibility rating
36.5 / 100
Poor credibility
Insolvency risk
Low
Elevated threat
Closure risk
39
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
Spółka wykazuje sygnały niestabilności organizacyjnej: częste zmiany nazwy spółki. Może to wskazywać na podwyższone ryzyko współpracy.
Shareholder changes
0
0/3 yrs
Board changes
1
1/3 yrs
PKD changes
0
0/3 yrs
Name changes
1
1/3 yrs
Data from 3 years of registry activity.
Credibility history
Payment reliability score from 2024–2026
Current: E (37/100)
Trend: improving (+6.5 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2024–2026
Current: 0 PLN
Safe: 0 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Pyramid Inventions
Founded
December 5, 2023
2 years in operation
Legal form
Limited Liability Company (LLC)
Registry: RejP
Headquarters
KRAKÓW
MAŁOPOLSKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Share capital
5.0 K PLN
100 shares total
Shareholders
3
shareholders
Filed years
3 years
2024–2026 · profitable: 0/3
Registry entries
10
latest: August 8, 2025
Risk signals
Revenue
0 PLN
2026
Net profit
-541.2 PLN
2026
Assets
0 PLN
2026
Equity
-16.0 K PLN
2026
Board and connected people - Pyramid Inventions
People holding roles at Pyramid Inventions according to the Polish National Court Register. Follow a name for that person's full profile and their other companies.
- Michał Tadeusz SułowskiPresident of the board, Majority shareholder, Other role
- Piotr Konrad SzatkowskiMajority shareholder
- Rafał TwarógMajority shareholder
Directories and rankings for this location
Public procurement
Trademarks
Reviews
Rate business credibility - Pyramid Inventions.
No ratings
Related articles
Explainer
Mabion in 2026: Polish monoclonal-antibody maker, mWIG40 issuer from Konstantynów Łódzki, Novavax COVID-19 antigen contract
Mabion S.A. (KRS 0000340462), headquartered at ul. Gen. Mariana Langiewicza 60 in Konstantynów Łódzki, is a Polish biotech specialising in monoclonal-antibody production (key project: MabionCD20, a rituximab biosimilar) and in CDMO (Contract Development and Manufacturing Organization) work. Its main international contract is manufacturing the COVID-19 vaccine antigen for Novavax. Founded in 2007 by Maciej Wieczorek and listed on the WSE since 2010, the company is an mWIG40 constituent, with a three-member management board and a five-member supervisory board.
Explainer
Ryvu Therapeutics in 2026: a Kraków oncology biotech, RVU120 in Phase II clinical trials, a six-member management board, an mWIG40 issuer after the Selvita spin-off
Ryvu Therapeutics S.A. (KRS 0000367359), headquartered at ul. Leona Henryka Sternbacha 2 in Kraków, is a Polish oncology biotech developing anti-cancer small-molecule drugs. It has operated as a stand-alone company since the 2019 spin-off from Selvita (which retained the R&D-services business). Flagship project: RVU120 – a CDK8/19 kinase inhibitor in Phase II trials across multiple oncological indications. Listed on the WSE since 2019 and an mWIG40 constituent, with a six-member management board and a seven-member supervisory board.